Cellanome

Cellanome is a biotechnology and life science tools company developing technologies to study living cells over time and connect cellular behavior with molecular information. Its mission is to create products that decipher cell biology to improve human health. The company aims to address a limitation of conventional research methods: measurements that capture cells at a single point in time can miss how they adapt, interact, and change.

Cellanome’s central offering is the R3200 Platform, an integrated system combining an instrument, flow cells, assays, consumables, and cloud software. It brings together fluorescent live-cell imaging and single-cell transcriptomics so researchers can relate observed cell behavior to molecular profiles from the same cells. The platform is intended for studies of individual cells as well as defined cell ensembles, preserving longitudinal context across experiments.

The system uses CellCage™ enclosures: biocompatible, tunable microenvironments designed to hold cells in place while supporting culture, time-lapse imaging, perturbations, and downstream sequencing. Researchers can apply stimuli and reagents, observe changes over time, and connect those observations with transcriptomic readouts. The R3200 automates parts of this workflow, including cell culture, reagent delivery, imaging, and RNA capture. Cellanome also describes cloud-based tools for planning runs and exploring multimodal results.

The company’s intended users include academic research laboratories and biopharmaceutical organizations. Cellanome identifies applications in oncology, immunology, neurobiology, and aging and metabolic disease. Examples of research questions described by the company include tumor–immune interactions, immune-cell responses, neural networks, and age-related cellular behavior. Its platform is designed to generate structured, longitudinal datasets that can help researchers investigate mechanisms, compare responses to perturbations, and support computational analysis.

Cellanome was founded in 2020 by Mostafa Ronaghi and other co-founders. The company is led by CEO Omead Ostadan and says it partners with academic labs and biopharma companies. Its official materials describe its work as building data infrastructure for biology and developing tools that connect cellular function, interactions, and molecular state. The company is based in Foster City, California, and lists additional offices in San Diego and Singapore.

Cellanome’s stated purpose is to improve understanding of cells and disease by helping scientists move beyond isolated snapshots toward observations that retain cell-level context over time. Its products are presented as research tools; the company describes their role as supporting discovery and therapeutic development, not as clinical diagnostic products. The company’s careers material emphasizes collaborative work across research, engineering, and commercial teams, while its recruiting statement highlights bringing diverse and talented people together to address complex biological problems.